Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma



Summary

A study reveals that Bifidobacterium species enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma (HCC). The mechanism involves Bifidobacterium modulating the gut microbiome, leading to increased IFN-γ production by CD8+ T cells within the tumor microenvironment. This enhancement is dependent on the JAK signaling pathway, as its activation is crucial for the anti-tumor effect of the combination therapy. The research demonstrates that Bifidobacterium supplementation can overcome resistance to anti-PD-1 treatment in HCC, offering a promising strategy to improve immunotherapy outcomes in patients with this challenging cancer.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!